Lv41
408 积分 2023-08-01 加入
World Stroke Organization (WSO): Global Stroke Fact Sheet 2022
1个月前
已完结
Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling
1个月前
已完结
Rifaximin alleviates intestinal barrier disruption and systemic inflammation via the PXR/NFκB/MLCK pathway and modulates intestinal Lachnospiraceae abundance in heat-stroke mice
2个月前
已完结
Antibiotics and Probiotics for Irritable Bowel Syndrome
2个月前
已完结
Italian guidelines for the management of irritable bowel syndrome
2个月前
已完结
Diagnosis and Treatment of Irritable Bowel Syndrome
2个月前
已完结
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
2个月前
已完结
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
2个月前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
2个月前
已完结
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
2个月前
已完结
皖公网安备34019202002308
